Unicycive Therapeutics Inc. (UNCY) has a regulatory catalyst to watch next month.
The company's lead drug candidate, oxylanthanum carbonate or OLC, is under FDA review for the treatment of hyperphosphatemia in chronic kidney disease or CKD patients on dialysis.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com